Vanguard Group Inc. Has $18.43 Million Stock Position in Biomea Fusion, Inc. (NASDAQ:BMEA)

Vanguard Group Inc. raised its holdings in Biomea Fusion, Inc. (NASDAQ:BMEA) by 1.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,339,428 shares of the company’s stock after purchasing an additional 21,835 shares during the quarter. Vanguard Group Inc.’s holdings in Biomea Fusion were worth $18,431,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of BMEA. Renaissance Technologies LLC lifted its position in shares of Biomea Fusion by 1.9% during the 4th quarter. Renaissance Technologies LLC now owns 63,000 shares of the company’s stock worth $531,000 after buying an additional 1,200 shares during the last quarter. Ameritas Investment Partners Inc. bought a new position in shares of Biomea Fusion in the second quarter worth about $36,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Biomea Fusion by 89.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,744 shares of the company’s stock valued at $65,000 after purchasing an additional 2,242 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of Biomea Fusion by 28.3% during the 3rd quarter. Deutsche Bank AG now owns 11,174 shares of the company’s stock valued at $154,000 after purchasing an additional 2,462 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Biomea Fusion by 316.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,251 shares of the company’s stock worth $45,000 after purchasing an additional 2,470 shares in the last quarter. Institutional investors and hedge funds own 96.72% of the company’s stock.

Biomea Fusion Price Performance

BMEA opened at $12.98 on Monday. Biomea Fusion, Inc. has a fifty-two week low of $8.13 and a fifty-two week high of $43.69. The firm has a market capitalization of $465.85 million, a P/E ratio of -3.75 and a beta of -0.53. The company’s 50-day moving average is $16.06 and its 200 day moving average is $14.19.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BMEA. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $14.00 target price (down previously from $51.00) on shares of Biomea Fusion in a research note on Tuesday, April 2nd. Truist Financial reaffirmed a “buy” rating and issued a $55.00 target price on shares of Biomea Fusion in a report on Monday, April 1st. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Biomea Fusion in a research note on Monday, April 1st. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $70.00 price objective on shares of Biomea Fusion in a research note on Wednesday, April 3rd. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $53.13.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.